Elevation of serum C-reactive protein in patients with OAB and IC/BPS implies chronic inflammation in the urinary bladder

Neurourology and Urodynamics

Volumn 30, Issue 3, 2011, Pages 417-420

  Chung, Shiu Dong ^a   Liu, Hsin Tzu ^b   Lin, Heng ^b   Kuo, Hann Chorng ^b  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

Author keywords

Inflammation; Interstitial cystitis; Overactive bladder symptoms

Indexed keywords

C REACTIVE PROTEIN; NERVE GROWTH FACTOR;

ADULT; AGED; ARTICLE; BLADDER; CHRONIC INFLAMMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; INTERSTITIAL CYSTITIS; MAJOR CLINICAL STUDY; MALE; OVERACTIVE BLADDER; PROTEIN BLOOD LEVEL; URINE LEVEL;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; CYSTITIS; CYSTITIS, INTERSTITIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVE GROWTH FACTOR; TAIWAN; UP-REGULATION; URINARY BLADDER, OVERACTIVE;

EID: 79952754857     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.20938     Document Type: Article

References (27)

1. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36. (Pubitemid 44175300)
2. Moorthy P, Lapitan MC, Quek PL, et al. Prevalence of overactive bladder in Asian men: An epidemiological survey. BJU Int 2004;93:528-31.
3. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn 2002;21:167-78. (Pubitemid 34195211)
4. Irwin DE, Mungapen L, Milsom I, et al. The economic impact of overactive bladder syndrome in six Western countries. BJU Int 2009;103:202-9.
5. Nickel JC, Roehrborn CG, O'Leary MP, et al. The relationship between prostate Inflammation and lower urinary tract symptoms: Examination of baseline data from the REDUCE trial. Eur Urol 2008;54:1379-84.
6. Kramer G, Marberger M. Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr Opin Urol 2006;16:25-9.
7. Rohrmann S, DeMarzo AM, Smit E, et al. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate 2005;62:27-33. (Pubitemid 39614290)
8. Saini R, Gonzalez RR, Te AE. Chronic pelvic pain syndrome and the overactive bladder: The inflammatory link. Curr Urol Rep 2008;9:314-9.
9. Comperat E, Reitz A, Delcourt A, et al. Histologic features in the urinary bladder wall affected from neurogenic overactivity-A comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. Eur Urol 2006;50:1058-64. (Pubitemid 44486475)
10. Apostolidis A, Jacques TS, Freeman A, et al. Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. Eur Urol 2008;53:1245-53.
11. Tyagi P, Barclay D, Zamora R, et al. Urine cytokines suggest an inflammatory response in the overactive bladder:Apilot study. Int Urol Nephrol 2009; Sep 26 [Epub ahead of print].
12. Liu HT, Tyagi P, Chancellor MB, et al. Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment. BJU Int 2009;104:1476-81.
13. Liu HT, Kuo HC. Urinary nerve growth factor levels are elevated in patients with overactive bladder and do not significantly increase with bladder distention. Neurourol Urodyn 2009;28:78-81.
14. Liu HT, Kuo HC. Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder. J Urol 2008;179:2270-4.
15. Miller LJ, Fischer KA, Goralnick SJ, et al. Nerve growth factor and chronic prostatitis/chronic pelvic pain syndrome. Urology 2002;59:603-8. (Pubitemid 34249905)
16. Lowe EM, Anand P, Terenghi G, et al. Increased nervegrowth factor levels inthe urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br J Urol 1997;79:572-7. (Pubitemid 28321098)
17. Panayi DC, Khullar V, Digesu GA, et al. Is ultrasound estimation of bladder weight a useful tool in the assessment of patients with lower urinary tract symptoms? Int Urogynecol J Pelvic Floor Dysfunct 2009;20:1445-9.
18. Lekskulchai O, Dietz HP. Detrusor wall thickness as a test for detrusor over-activity in women. Ultrasound Obstet Gynecol 2008;32:535-9.
19. Chung SD, Chiu B, Kuo HC, et al. Transabdominal ultrasonography of detrusor wall thickness in women with overactive bladder. BJU Int 2010;105:668-72.
20. St. Sauver JL, Sarma AV, Jacobson DJ, et al. Association between C-reactive protein levels and longitudinal changes in Urologic measures. J Urol 2008; 179:S30.
21. Andersson KE. LUTS treatment: Future treatment options. Neurourol Urodyn 2007;26:934-47.
22. Di Silverio F, Bosman C, Salvatori M, et al. Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Eur Urol 2005;47:72-9. (Pubitemid 39575721)
23. Ozdemir I, Bozkurt O, Demir O, et al. Combination therapy with doxazosin and tenoxicam for the management of lower urinary tract symptoms. Urology 2009;74:431-5.
24. Kupelian V, McVary KT, Barry MJ, et al. Association of C-reactive protein and lower urinary tract symptoms in men and women: Results from Boston Area Community Health survey. Urology 2009;73:950-7.
25. Jang J, Park EY, Seo SI, et al. Effects of intravesical instillation of cyclooxygenase-2 inhibitor on the expression of inducible nitric oxide synthase and nerve growth factor in cyclophosphamide-induced overactive bladder. BJU Int 2006;98:435-9.
26. Dupont MC, Spitsbergen JM, Kim KB, et al. Histological and neurotrophic changes triggered by varying models of bladder inflammation. J Urol 2001;166:1111-8. (Pubitemid 32751054)
27. Gonzalez RR, Fong T, Belmar N, et al. Modulating bladder neuro-inflammation: RDP58, a novel anti-inflammatory peptide, decreases inflammation and nerve growth factor production in experimental cystitis. J Urol 2005;173:630-4.